艾爾建(英語:Allergan plc),或譯愛力根,是一家愛爾蘭製藥公司,AbbVie的子公司。[2][1]

艾爾建
Allergan plc
公司類型子公司
ISINIE00BY9D5467
成立2013年5月16日,​11年前​(2013-05-16
總部 愛爾蘭都柏林
營業據點數40家生產工廠,27家全球研發中心和全球銷售營銷部門
業務範圍100個國家
產業製藥工程
營業額 157.87億美元 (2018年)
淨收入 51.42億美元 (2018年)
資產 1017.87億美元 (2018年)
資產淨值 651.31億美元 (2018年)
所有權者艾伯維 編輯維基數據
員工人數17,800 (2018)
網站www.allergan.com
備註[1]

歷史

1950年創建於美國歐文,1970年在紐約證券交易所掛牌上市,2009年進入中國市場,2015年被愛爾蘭製藥公司阿特維斯以700億美元收購,並且將總部遷往都柏林以避稅。[3][4]合併後的公司依然使用原名。

2015年11月23日,輝瑞宣佈斥資1,600億美元打算收購艾爾建。但在2016年4月6日,因奧巴馬政府禁止稅負倒置,輝瑞取消收購計劃[5],輝瑞賠償艾爾建中止協議補償金1.5億美元[6][7]

2019年6月,美國製藥公司AbbVie宣佈已達成協議,以630億美元收購艾爾建。

 
艾爾建美國總部
 
艾爾建愛爾蘭總部

參考來源

  1. ^ 1.0 1.1 Allergan plc 2018 Form 10-K Annual Report. U.S. Securities and Exchange Commission. [2019-09-30]. (原始內容存檔於2019-09-30). 
  2. ^ Jonathan D. Rockoff; Nina Trentmann. New Tax Law Haunts Inversion Deals. The Wall Street Journal. 11 February 2018. Similarly, Allergan, a drugmaker that moved its headquarters to Ireland after a 2013 acquisition but gets about 80% of revenue in the U.S., expects the loss of deductions on intercompany loans will largely be balanced out by lower taxes on its U.S. sales. 
  3. ^ From Actavis to Allergan: One pharma company's wild dealmaking journey. Forbes Magazine. 30 July 2015 [2019-09-30]. (原始內容存檔於2020-09-27). For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud. 
  4. ^ Liz Hoffman. The Tax Inversion Wave Keeps Rolling. Wall Street Journal. 7 July 2015 [2019-09-30]. (原始內容存檔於2019-04-17). Horizon and other inverted companies are using their new, lower tax rates to turbocharge corporate takeovers. Applying those rates, often in the midteens, to profits of companies in the U.S., with a federal corporate rate of 35%, can yield extra savings on top of those traditionally wrung from mergers. Moreover, unlike the U.S., Ireland and most other countries, only tax profits earned in-country, giving companies the freedom and incentive to shift income to still-lower-tax jurisdictions. 
  5. ^ Pfizer seals $160bn Allergan deal to create drugs giant. BBC News. November 23, 2015 [2022-02-18]. (原始內容存檔於2020-11-27). 
  6. ^ Rockoff, Jonathan. Pfizer Walks Away From Allergan Deal. The Wall Street Journal. April 6, 2016 [2022-02-18]. (原始內容 存檔於2022-02-18). 
  7. ^ Hoffman, Richard Rubin and Liz. New Rules on Tax Inversions Threaten Pfizer-Allergan Deal. Wall Street Journal. 2016-04-05 [2020-04-08]. ISSN 0099-9660. (原始內容存檔於2022-02-18) (美國英語). 

外部連結